How immune-related adverse events differ in elderly gastrointestinal vs. lung cancer patients
Peer-Reviewed Publication
Updates every hour. Last Updated: 23-Jun-2026 01:16 ET (23-Jun-2026 05:16 GMT/UTC)
Immune checkpoint inhibitors are widely used in elderly cancer patients, but data on tumor-specific immune-related adverse events (irAEs) remain limited. A Chinese Medical Journal study analyzed 407 elderly patients with gastrointestinal (GI) tumors or lung cancer. Results showed higher irAE incidence in lung cancer patients, skin toxicity more prevalent in GI tumor patients, and thyroid dysfunction more common in lung cancer patients. This study provides evidence for personalized safety management of immunotherapy in elderly patients.
Predicting whether a healthy 45-year-old will struggle to climb stairs or walk a decade later has long been a challenge for geriatric medicine. Now, a study published in JMIR Aging, a leading open access journal from JMIR Publications, reveals that early mobility decline can be predicted using a simple set of home-based measurements and artificial intelligence.
For decades, scientists have known that estrogen protects cardiovascular health, but exactly how that protection works—and what happens when it disappears—has remained unclear. New research from University of Texas at Arlington points to the liver and the immune system as critical players.
Microbes beneath our feet quietly orchestrate the health of ecosystems, but their seasonal rhythms remain a mystery—especially in coastal wetlands.
Complimentary press passes are available for qualifying journalists to attend NUTRITION 2026, the annual flagship meeting of the American Society for Nutrition. Join thousands of nutrition researchers and professionals to examine the latest science shaping national conversations July 25–28 in National Harbor, Maryland, just outside Washington, D.C.
Shanghai, China, May 12, 2026 --- Insilico Medicine ("Insilico", 03696.HK), a biotechnology company powered by generative artificial intelligence, today announced that the company has entered a strategic collaboration agreement with Suzhou Ribo Life Science Co., Ltd. ("Ribo", 06938.HK), a globally leading clinical-stage company in oligonucleotide therapeutics. Building upon the automation, intelligence and scalability capabilities of Insilico's LifeStar 2 laboratory, the two parties will further deepen the existing experimental service cooperation, combining the end-to-end R&D capabilities of Insilico's proprietary Pharma.AI platform with Ribo's profound expertise in oligonucleotide therapeutics development, aiming for comprehensive efficiency boost in the oligonucleotide drug R&D cycle.
Korea University's College of Medicine (Dean Pyun Sung-bom) has been simultaneously selected for the undergraduate and graduate programs of the '2026 Convergence Physician-Scientist Training Project' organized by the Korea Health Industry Development Institute.
A new Society of Interventional Radiology (SIR) position statement provides evidence-based support for the use of genicular artery embolization (GAE) as a minimally invasive treatment option for patients with symptomatic knee osteoarthritis (KOA) who have failed conservative therapy and are not candidates for, or wish to delay, total knee arthroplasty.